Qbiotics Pty Ltd

Peplin Research Pty Ltd

Griffith University

Qbiotics Limited

Leo Laboratories Limited

Peter Gordon Parsons

Paul Warren Reddell

Victoria Anne Gordon

Glen Mathew Boyle

James Harrison Aylward

Andreas Suhrbier

Ryan Moseley

Robert Steadman

Rachael Louise Moses

Kathleen Anne Turner

Jason Kingsley Cullen

Richard John Bowen

Susan Jane Berners-Price

David William Thomas

Lydia Charlotte Powell

Manon F Pritchard

Katja Etel Hill

The present invention relates to methods of treating tumours comprising the localised administration, for example, intratumourally or topically, of an epoxytiglienone compound (as a monotherapy) to cancerous tumours to generate a systemic anticancer abscopal (anenestic) and/or bystander effect.

Method of treating tumours

The present invention relates to a combination therapy for tumours comprising the administration of an epoxytigliane compound and an immune checkpoint inhibitor. In particular embodiments, there is a method of treating a tumour and/or treating or preventing one or more bystander tumours with the therapy. Pharmaceutical compositions and kits containing epoxytigliane compounds and immune checkpoint inhibitors are also described.

Combination therapy for the treatment or prevention of tumours

The present invention relates to epoxy-tigliane compounds and their use in promoting wound healing. In particular embodiments, the epoxy-tigliane compounds are epoxy-tigliaen-3-one compounds. Methods of inducing or promoting wound healing as well as methods of reducing scarring and improving cosmetic outcomes upon healing of a wound are described. Compounds and compositions for use in wound healing are also described.

Methods and compositions for wound healing

The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogs or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species. The present invention further contemplates a method for the prophylaxis or treatment of mammalian, animal or avian subjects for inflammatory conditions including chronic or transitory inflammatory conditions or for ameliorating the symptoms of an inflammatory condition by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Euphorbiaceae family or botanical or horticultural relatives thereof or a derivative, chemical analog or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or be in the form of a chemical fraction, sub-fraction or preparation or extract of the plant.

Topical use of ingenol-3-angelate or a salt thereof to treat skin cancer

The present invention relates to the treatment of acnein a subject by administering to the subject an ingenane of the formula wherein R-Rare herein defined.

Macrocyclic diterpenes for the treatment and prophylaxis of acne vulgaris

The present invention relates generally to chemical agents useful in the treatment and prophylaxis of infection by pathogenic or potentially pathogenic entities, or entities capable of opportunistic infection in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of infection by pathogenic entities in mammalian, animal and avian subjects. The present invention further contemplates a method for the prophylaxis and/or treatment in mammalian, animal or avian subjects of infection or potential infection by pathogenic entities by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Euphorbiaceae family of plants or their botanical or horticultural derivatives or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or in the form of a chemical fraction, sub-fraction, preparation or extract of the plant.

Therapeutic agents&#x2014;I

A chemical agent of the diterpene family obtained from a member of the Euphorbiaceae family of plants for use in the treatment of prophylaxis of prostate cancer or a related cancer or condition.

Treatment of prostate cancer

A method of treatment or inhibition of tumors including the steps of: (i) exchanging one or more of the eight phenyl substituents in the compound &lsqb;M(dppe),&rsqb;,where M is selected from Au(I), Ag(I) and Cu(I) by 2, 3, or 4 pyridyl substituents to provide a compound having anti-tumor activity and an octanol/water partition coefficient between 0.01 and 25.5; and (ii) administering said compound to a subject requiring treatment which compound has selective toxicity to cancer cells including cisplatin resistant human carcinoma cell lines. The invention also includes within its scope compounds of formula (I)

Anti-tumor agents comprising pyridyl-substituted metal-diphosphine complex

A method of treatment or inhibition of tumors involves administering a compound to a subject. The compound is one in which one or more of the eight phenyl substituents in the compound [M(dppe).sub.2 ].sup.+, in which M is selected from Au(I), Ag(I) and Cu(I), is substituted by 2, 3, or 4 pyridyl substituents. The compound has anti-tumor activity and an octanol/water partition coefficient between 0.01 and 25.5. The compound has selective toxicity to cancer cells, including cisplatin resistant human carcinoma cells lines.

Growing community of inventors

St. Lucia, Australia

Peter Gordon Parsons